Diabetic Macular Edema Clinical Trials

30 recruiting

Diabetic Macular Edema Trials at a Glance

42 actively recruiting trials for diabetic macular edema are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Phase 1 with 11 trials, with the heaviest enrollment activity in Shanghai, San Antonio, and Abilene. Lead sponsors running diabetic macular edema studies include Hoffmann-La Roche, EyePoint Pharmaceuticals, Inc., and Alexandria University.

Browse diabetic macular edema trials by phase

Treatments under study

About Diabetic Macular Edema Clinical Trials

Looking for clinical trials for Diabetic Macular Edema? There are currently 30 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diabetic Macular Edema trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diabetic Macular Edema clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 42 trials

Recruiting
Phase 3

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

Diabetic Macular Edema
Alvotech Swiss AG256 enrolled1 locationNCT07489131
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

Diabetic Macular Edema
Genentech, Inc.93 enrolled8 locationsNCT07425522
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Hoffmann-La Roche850 enrolled59 locationsNCT06680817
Recruiting
Not Applicable

Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

Diabetic Retinopathy (DR)Diabetic Macular Edema (DME)
Osijek University Hospital100 enrolled1 locationNCT07520045
Recruiting
Phase 3

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Diabetic Macular Edema (DME)Diabetic Macular EdemaDME
EyePoint Pharmaceuticals, Inc.240 enrolled38 locationsNCT07449923
Recruiting
Phase 3

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Diabetic Macular Edema (DME)Diabetic Macular EdemaDME
EyePoint Pharmaceuticals, Inc.240 enrolled39 locationsNCT07449936
Recruiting
Phase 3

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema

Diabetic Macular Edema (DME)
Bio-Thera Solutions406 enrolled50 locationsNCT07515079
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

Diabetic Macular Edema
Genentech, Inc.546 enrolled78 locationsNCT06850922
Recruiting
Phase 4

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

Diabetic Macular Edema (DME)
Harrow Inc236 enrolled1 locationNCT07456826
Recruiting
Early Phase 1

Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients

Diabetic Macular Edema (DME)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine32 enrolled2 locationsNCT07362927
Recruiting
Phase 1Phase 2

Kamuvudine-9 (K9) in Diabetic Macular Edema

Diabetic Macular Edema
Dr. Bryan Strelow10 enrolled1 locationNCT07458061
Recruiting
Phase 3

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

Diabetic Macular Edema
Hoffmann-La Roche634 enrolled92 locationsNCT04108156
Recruiting

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Hoffmann-La Roche1,000 enrolled41 locationsNCT06439576
Recruiting
Phase 1

A Study of Avoralstat In Participants With Diabetic Macular Edema

Diabetic Macular Edema (DME)
BioCryst Pharmaceuticals9 enrolled8 locationsNCT07228559
Recruiting

Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema

TreatmentRefractoryMicropulse Laser+2 more
The General Authority for Teaching Hospitals and Institutes50 enrolled1 locationNCT07295704
Recruiting
Phase 2

Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema

Diabetic RetinopathyDiabetic Macular Edema
Carmen Clapp120 enrolled2 locationsNCT03161652
Recruiting
Not Applicable

Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetic Retinopathy+3 more
Vastra Gotaland Region40 enrolled1 locationNCT06549023
Recruiting
Not Applicable

Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

Diabetes MellitusOxidative StressHyperglycaemia (Diabetic)+4 more
Vastra Gotaland Region150 enrolled2 locationsNCT06984822
Recruiting
Phase 1

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

Diabetic RetinopathyDiabetic Macular EdemaMacular Edema+2 more
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.45 enrolled3 locationsNCT04187443